Cited by 874HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 73 of the 83 references it cites were found in a registry or an index.

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Open access

Agus, David B, Akita, Robert W, Fox, William D, Lewis, Gail D, Higgins, Brian, Pisacane, Paul I, Lofgren, Julie A, Tindell, Charles, Evans, Douglas P, Maiese, Krista, Scher, Howard I, Sliwkowski, Mark X·2002·Cancer Cell

DOI 10.1016/s1535-6108(02)00097-1

Open this paper in CoChat — free account Open PDF

Abstract

ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in both low- and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00097-1

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citation
Real time quantitative PCR.Preprint
Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
A novel method for real time quantitative RT-PCR.Preprint
Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617
The EGF receptor family as targets for cancer therapy
Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Show all 83 references

Research works printed but not linked: 6

Agus, 1999, Prostate cancer cell cycle regulators, J. Natl. Cancer Inst., 91, 1869, 10.1093/jnci/91.21.1869 · DOI
Lewis, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin, Cancer Res., 56, 1457
Nagabhushan, 1996, CWR22, Cancer Res., 56, 3042
Pinkas-Kramarski, 1996, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO J., 15, 2452, 10.1002/j.1460-2075.1996.tb00603.x · DOI
Tzahar, 1998, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas, Biochim. Biophys. Acta, 1377, M25
Wainstein, 1994, CWR22, Cancer Res., 54, 6049

Sorted by citations

Items 801–874 of 874

Novel Players in the Integrin Signaling Orchestra: TCPTP and MDGI
Nevo, J. (2011) · UTUPub (University of Turku)
Role of ErbB2 and ErbB4 in Cancer Growth, Prognosis and as Targets for Immunotherapy
Hollmén, M. (2010) · UTUPub (University of Turku)
Dendritic cell based cancer vaccines using adenovirally mediated expression of the HER-2/neu gene and apoptotic tumor cells expressing heat shock protein 70
Chan, T. H. M. (2006) · University Library - University of Saskatchewan (University of Saskatchewan)
Amplification and Overexpression of ERBB2, uPA, TRPS1, EIF3S3 and MYC Genes in Prostate Cancer
Savinainen, K. (2006) · Tampere University Institutional Repository (Tampere University)
Novel HER2-targeted agents for breast cancer therapy
Abraham, J. (2011) · Community Oncology · doi:10.1016/s1548-5315(12)70077-3
Molecular mechanisms controlling endocytic downregulation of EGFR and ErbB3
Sak, M. M. (2013) · NORA - Norwegian Open Research Archives
Human Epidermal Growth Factor Receptor (HER) Family Molecular Structure
Pegram, M. D., & Landgraf, R. (2016) · Springer eBooks · doi:10.1007/978-4-431-55552-0_19
Targeted Prostate Cancer Chemoprevention Trial with Tocotrienols
Stone, W., Palau, V. E., Campbell, S., & Krishnan, K. (2012) · CRC Press eBooks · doi:10.1201/b12502-9
Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer
Ghosh, P., Qiu, Y., Wang, L., & Kung, H. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.009
HER-2 as a Prognostic and Predictive Biomarker in Cancer
Zimmer, A. S., Wedamb, S. B., & Lipkowitza, S. (2020) · doi:10.1201/9781003159469-4
Monoclonal Antibodies Targeting EGFR/HER2 and Clinical Outcomes in Cancer Treatment
Vermorken, J. B. (2013) · doi:10.2217/9781780843278
Targeting HER2+ and trastuzumab-resistant metastatic breast cancer
Cortés, J., & Scaltriti, M. (2011) · CRC Press eBooks · doi:10.3109/9781841848129-6
Pertuzumab : un nouvel agent dans la prise en charge du cancer du sein HER2 positif Données des études précliniques et cliniques Pertuzumab: a new agent in HER2-positive breast cancer Data from preclinical and clinical studies
Launay‐Vacher, V., Spano, J., & Rey, J. (2012)
Interrogation of the Limitations and Capabilities of the Model-Gel-Tissue Assay and Application to Soft Tissue Modulus Evaluation
Barnes, S. L. (2011)
Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab Toru KawamotoKazunori IshigeMelanie ThomasYoriko Yamashita-Kashima • Sei ShuNobuyuki IshikuraShunichi AriizumiMasakazu Yamamoto •
Shoda, K. K. (2015)
Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R
Kaumaya, P. T. P., & Bekaii‐Saab, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12422-9
Crosstalk and modulation of signaling between somatostatin and growth factor receptors in human breast cancer cell lines
Zhou, J. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0354252
[Assessment of the effectiveness of Androcur in the treatment of precocious puberty].
Tv, S. (1989) · PubMed
Design, Synthesis and Characterization of Conformational Peptides at the Interface of HER-2 Dimerization and Pertuzumab Binding
Steele, J. T., Rawale, S. V., & Kaumaya, P. T. P. (2010) · Springer eBooks · doi:10.1007/978-0-387-26575-9_278
Noncardiac Toxicity of HER2-Targeted Therapy
Master, A. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-58122-6.00011-8
The Role of the Ste20-like Kinase in Embryonic Development and Neu-induced Mammary Tumorigenesis
Al‐Zahrani, K. N. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-22866
Current Treatment Options and New Developments in Metastatic Breast Cancer
Arslan, Ü. Y., & Öksüzoğlu, B. Ç. (2019) · Acta Oncologica Turcica · doi:10.5505/aot.2019.99266
Complete Response to Trastuzumab and Pertuzumab in Combination with Chemotherapy in HER2-positive Metastatic Breast Cancer—Case Series—
Tsuchida, Y., Hayashi, N., Toshikawa, C., Yamashita, Y., Suzuki, K., & Yamauchi, H. (2019) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.80.480
Retraction Note to: SOX2 oncogenes amplified and operate to activate AKT signalling in gastric cancer and predict immunotherapy responsiveness
Tian, Y., Jia, X., Wang, S., Li, Y., Zhao, P., Cai, D., Zhou, Z., Wang, J., Luo, Y., & Dong, M. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-02878-3
Retracted
Pertuzumab et T-DM1 : de nouvelles perspectives dans le traitement du cancer du sein HER2 positif Pertuzumab and T-DM1: New Perspectives in the Treatment of HER2-positive Breast Cancer
Guiu, S., Fumoleau, P., & Sas, L. (2015)
HER-2 as a Prognostic and Predictive Biomarker in Cancer
Wedam, S. B., & Lipkowitz, S. (2013) · Pan Stanford Publishing eBooks · doi:10.1201/b15029-5
HER2-Positive (HER2 +) Breast Cancer
Dilday, T., & Yeh, E. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00055-4
Identification of the Her-2 Functional Site: Blockage of Receptor Heterodimerization
Lupu, R. (2007) · Defense Technical Information Center (DTIC)
Monoclonal Antibodies
Laster, B. H., & Gopas, J. (2006) · Encyclopedia of Medical Devices and Instrumentation · doi:10.1002/0471732877.emd177
Tiermodelle in der biomedizinischen Forschung
Strehle, M., & Britisch, S. (2008) · Springer eBooks · doi:10.1007/978-3-540-69414-4_9
Epidermal growth factor receptor family activation and intracellular signaling
Richman, J. M. (2008) · doi:10.17760/d10016788
Targeting HER2+and trastuzumab-resistant metastatic breast cancer
Cortés, J., & Scaltriti, M. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848129.004
Pertuzumab (Perjeta®)
Garca‐Saénz, J. A., Antón, F. M., & Bueno, C. (2014) · doi:10.1002/9783527682423.ch67
News in brief
Ashton, V., Brown, M., CLOUGH, J. B., Owens, J., Sheikh, S., & Wild, C. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02447-9
Therapeutic Antibodies and Immunologic Conjugates
Cheung, N. V. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50038-5
Breast cancer
Altıntaş, S. (2013) · doi:10.2217/ebo.13.205
Breast cancer immunotherapy and personalized medicine
(2022) · American Journal of BioMedicine · doi:10.18081/2333-5106/2022.10/146
Data from A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E. S., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2023) · doi:10.1158/0008-5472.c.6497672
Self-citation
Data from Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Scheuer, W., Friess, T., BURTSCHER, H. J., Bossenmaier, B., Endl, J., & Hasmann, M. (2023) · doi:10.1158/0008-5472.c.6499707.v1
Data from Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Chen, L., Mooso, B. A., Jathal, M. K., Madhav, A., Johnson, S. D., Spyk, E. N. V., Mikhailova, M., Ripoll, A. Z., Xue, L., Vinall, R. L., et al. (2023) · doi:10.1158/1078-0432.c.6518943
Data from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Collins, D. M., Madden, S. F., Gaynor, N., AlSultan, D., Gal, M. L., Eustace, A. J., Gately, K. A., Hughes, C., Davies, A. M., Mahgoub, T., et al. (2023) · doi:10.1158/1078-0432.c.6530235
Data from Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab
Yao, E. S., Zhou, W., Lee-Hoeflich, S. T., Truong, T., Haverty, P. M., Eastham‐Anderson, J., Lewin‐Koh, N., Gunter, B., Belvin, M. P., Murray, L. J., et al. (2023) · doi:10.1158/1078-0432.c.6517759.v1
Self-citation
Data from Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
Chen, L., Mooso, B. A., Jathal, M. K., Madhav, A., Johnson, S. D., Spyk, E. N. V., Mikhailova, M., Ripoll, A. Z., Xue, L., Vinall, R. L., et al. (2023) · doi:10.1158/1078-0432.c.6518943.v1
Data from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Collins, D. M., Madden, S. F., Gaynor, N., AlSultan, D., Gal, M. L., Eustace, A. J., Gately, K. A., Hughes, C., Davies, A. M., Mahgoub, T., et al. (2023) · doi:10.1158/1078-0432.c.6530235.v1
Conformational diversity and protein-protein interface clusters help drug repurposing in Ras/Raf/MEK/ERK signaling pathwayPreprint
Sayin, A. Z., Abali, Z., Senyuz, S., Cankara, F., Gürsoy, A., & Keskin, Ö. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.03.551801
Additional file 9 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Raghavendra, A. S., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304887
HER Receptor, Current, and Emerging Therapeutic Targets
Tan, M. L., Yeap, J. W., & Matawali, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_258
Multiscale Computational Studies of PEG Chain Length Effects on HER2 mAb Fc Structure and Binding Energetics
Noriega, H. A., Akala, E. O., & Wang, X. S. (2025) · ACS Omega · doi:10.1021/acsomega.5c08654
Molecular interactions of ErbB receptor tyrosine kinases - with an outlook on their therapeutic targeting
Friedländer, E. (2008) · University of Debrecen Electronic Archive (University of Debrecen)
Additional file 1 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Singareeka Raghavendra, A., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304863
Additional file 6 of PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Liu, X., liu, Z., Li, C., Song, X., Wang, X., Li, S., & Yu, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24159433
Additional file 2 of PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Liu, X., liu, Z., Li, C., Song, X., Wang, X., Li, S., & Yu, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24159421
Additional file 3 of PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Liu, X., liu, Z., Li, C., Song, X., Wang, X., Li, S., & Yu, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24159424
Additional file 4 of PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Liu, X., liu, Z., Li, C., Song, X., Wang, X., Li, S., & Yu, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24159427
Additional file 2 of A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
Wege, A. K., Kirchhammer, N., Kazandjian, L. V., Prassl, S., Brandt, M., Piendl, G., Ortmann, O., Fischer, S., & Brockhoff, G. (2020) · Figshare · doi:10.6084/m9.figshare.12813643
Additional file 2 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Singareeka Raghavendra, A., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304866
Additional file 8 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Singareeka Raghavendra, A., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304884
Additional file 1 of PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Liu, X., liu, Z., Li, C., Song, X., Wang, X., Li, S., & Yu, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24159418
Additional file 6 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Singareeka Raghavendra, A., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304878
Additional file 3 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Singareeka Raghavendra, A., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304869
Additional file 5 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Singareeka Raghavendra, A., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304875
Additional file 7 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Singareeka Raghavendra, A., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304881
Additional file 5 of PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Liu, X., liu, Z., Li, C., Song, X., Wang, X., Li, S., & Yu, Z. (2023) · Figshare · doi:10.6084/m9.figshare.24159430
Additional file 4 of Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
Liu, S., Xie, S. M., Liu, W., Gagea, M., Hanker, A. B., Nguyen, N., Singareeka Raghavendra, A., Yang-Kolodji, G., Chu, F., Neelapu, S. S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23304872
Additional file 1 of Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Rönnlund, C., Sifakis, E. G., Schagerholm, C., Yang, Q., Karlsson, E., Chen, X., Foukakis, T., Weidler, J. M., Bates, M., Fredriksson, I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26677907
Insights from Genomic Sequencing of Preclinical Breast Cancer Models Establish Human Parallels to Increase Therapeutic Applicability
Schulte, A., & Andrechek, E. R. (2026) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-026-09599-7 · Cited by 1
Ciblage de l'entité HER2/HER3 par des anticorps monoclonaux pour le traitement des cancers du pancréas exprimant faiblement HER2.
Thomas, G. (2013) · doi:10.70675/51738fd1z010ez4b98zb09ezda50c8374f94
Development and characterization of models of resistance to T-DM1
Sauveur, J. (2016) · doi:10.70675/0446084czf985z40d7zab04zef93799e94a2
Développement d'une approche de protéomique quantitative appliquée au diagnostic des cancers du sein HER2 positif
Guérin, M. (2018) · theses.fr (ABES) · doi:10.70675/50d0236fz46aaz4702z81c5z3e195b918afe
Structural and functional investigation of the C-terminal intrinsically disordered fragment of ErbB2
Pinet, L. (2019) · theses.fr (ABES) · doi:10.70675/475c3429zc6c3z40ffz8928zcf02d751d48d · Cited by 1
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum
Tarantino, P., Valenza, C., Seguí, E., Lin, N., Prat, A., Curigliano, G., Waks, A. G., & Tolaney, S. M. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01211-5
Acknowledgements
Pérez-García, J. M., Muñoz‐Couselo, E., Ortega, V., & Cortés, J. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.46
Stop signals
Greenwood, E. (2002) · Nature reviews. Cancer · doi:10.1038/nrc892
Comment augmenter la performance des médicaments anti-HER?
Dalenc, F., Bergé, Y., & Roche, H. H. (2012) · Springer eBooks · doi:10.1007/978-2-8178-0245-9_34

Authors: Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., Scher, H. I., & Sliwkowski, M. X.
Affiliations: Cedars-Sinai Medical Center (US)
Genentech (US)
Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Sliwkowski, Mark X
ORCID: Agus, David B
Scher, Howard I
Sliwkowski, Mark X
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2002-08
Volume: 2
Issue: 2
Pages: 127-137
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/s1535-6108(02)00097-1
OpenAlex: W2014457594
Cited by: 873
References: 83
Citations by year: 2026: 2 · 2025: 10 · 2024: 21 · 2023: 38 · 2022: 21 · 2021: 21 · 2020: 28 · 2019: 29 · 2018: 27 · 2017: 24 · 2016: 38 · 2015: 48 · 2014: 69 · 2013: 59 · 2012: 51
FWCI: 16.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 4003 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: PepsiCo
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: ERBB2, HER2, HER3, neuregulin-1, ErbB receptor family, breast cancer, prostate cancer, tumor growth inhibition, tyrosine kinase inhibitors
MeSH terms: Androgens, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Cell Division, Female, Humans, Ligands, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Binding, RNA, Messenger, Time Factors, Transplantation, Heterologous, Tumor Cells, Cultured, Signal Transduction, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Neuregulin-1, Receptor, ErbB-3, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks